{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:05Z","timestamp":1789745405015,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PharmaEssentia Corporation"},{"DOI":"10.13039\/501100006452","name":"University of Miyazaki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006452","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by clonal erythrocytosis. A phase 2 study reported that ropeginterferon alfa-2b is a well-tolerated and effective treatment for PV in Japanese patients. This post hoc analysis of the phase 2 data further evaluated outcomes in patients at low risk of thrombosis (low-risk PV). Among 20 patients with low-risk PV, 60.0% (12\/20) and 85.0% (17\/20) achieved\u2009&lt;\u200945% hematocrit by weeks 24 and 52, respectively. The proportion of responders with complete hematologic response (CHR) was 60.0% (12\/20) at week 52, and the median time to response was 11.9\u00a0months. The mean <jats:italic>JAK2<\/jats:italic> V617F allele burden decreased from 75.8% at baseline to 53.7% at week 52. No patient experienced thrombosis or bleeding episodes. All patients experienced treatment-emergent adverse events (TEAEs) related to ropeginterferon alfa-2b, but no grade\u2009\u2265\u20093 TEAEs or deaths related to ropeginterferon alfa-2b occurred, and no new safety concerns arose. This analysis indicated that ropeginterferon alfa-2b may be an effective treatment option for Japanese patients with low-risk PV.<\/jats:p>","DOI":"10.1007\/s12185-024-03804-1","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T16:02:06Z","timestamp":1719849726000},"page":"151-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety outcomes in Japanese patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b"],"prefix":"10.1007","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2555-8188","authenticated-orcid":false,"given":"Kazuya","family":"Shimoda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Kirito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"3804_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1208500","volume":"368","author":"R Marchioli","year":"2013","unstructured":"Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, CYTO-PV Collaborative Group, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22\u201333.","journal-title":"N Engl J Med"},{"key":"3804_CR2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in Oncology: Myeloproliferative neoplasms. Version 1. 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477. Accessed 20 Jan 2024."},{"key":"3804_CR3","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","volume":"9","author":"M Marchetti","year":"2022","unstructured":"Marchetti M, Vannucchi AM, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9:e301\u201311.","journal-title":"Lancet Haematol"},{"key":"3804_CR4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12185-020-02964-0","volume":"112","author":"K Shimoda","year":"2020","unstructured":"Shimoda K, Takahashi N, Kirito K, Iriyama N, Kawaguchi T, Kizaki M. JSH practical guidelines for hematological malignancies, 2018: I Leukemia-4 Chronic myeloid leukemia (CML)\/myeloproliferative neoplasms (MPN). Int J Hematol. 2020;112:268\u201391.","journal-title":"Int J Hematol"},{"key":"3804_CR5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020232","author":"AT Gerds","year":"2023","unstructured":"Gerds AT, Mesa RA, Burke JM, Grunwald MR, Stein BL, Squier P, et al. Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL. Blood. 2023. https:\/\/doi.org\/10.1182\/blood.2023020232.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3804_CR6","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1182\/blood-2023-182706","volume":"142","author":"K Shimoda","year":"2023","unstructured":"Shimoda K, Yasunaga H, Sugimoto Y, Uenaka H, Dochi T, Jun G. The association between blood cell counts and thrombotic events in Japanese patients with polycythemia vera: a retrospective database study. Blood. 2023;142(Supplement 1):3191.","journal-title":"Blood"},{"key":"3804_CR7","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1182\/blood.2022017697","volume":"141","author":"AR Moliterno","year":"2023","unstructured":"Moliterno AR, Kaizer H, Reeves BN. JAK2 V617F allele burden in polycythemia vera: burden of proof. Blood. 2023;141:1934\u201342.","journal-title":"Blood"},{"key":"3804_CR8","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva-Kyuchukova L, Egyed M, PROUD-PV Study Group, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7:e196\u2013208.","journal-title":"Lancet Haematol"},{"key":"3804_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s12185-022-03341-9","volume":"116","author":"Y Edahiro","year":"2022","unstructured":"Edahiro Y, Ohishi K, Gotoh A, Takenaka K, Shibayama H, Shimizu T, et al. Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 study. Int J Hematol. 2022;116:215\u201327.","journal-title":"Int J Hematol"},{"key":"3804_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/EVIDoa2200335","volume":"2","author":"T Barbui","year":"2023","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evid. 2023;2:1.","journal-title":"NEJM Evid"},{"key":"3804_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/sj.leu.2404955","volume":"22","author":"A Teferi","year":"2008","unstructured":"Teferi A, Vardiman JW. Classification and diagnosis of myelo-proliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14\u201322.","journal-title":"Leukemia"},{"key":"3804_CR12","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"3804_CR13","doi-asserted-by":"publisher","first-page":"843","DOI":"10.2169\/internalmedicine.2171-23","volume":"63","author":"K Kirito","year":"2024","unstructured":"Kirito K. Silent thyroiditis associated with ropeginterferon alfa-2b in a patient with polycythemia vera. Intern Med. 2024;63:843\u20136.","journal-title":"Intern Med"},{"key":"3804_CR14","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1007\/s00277-022-04963-z","volume":"101","author":"A Triguero","year":"2022","unstructured":"Triguero A, Pedraza A, P\u00e9rez-Encinas M, Mata-V\u00e1zquez MI, V\u00e9lez P, Fox L, On behalf of the MPN Spanish Group (GEMFIN), et al. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. Ann Hematol. 2022;101:2231\u20139.","journal-title":"Ann Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03804-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03804-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03804-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T19:04:49Z","timestamp":1722193489000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03804-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3804"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03804-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"4 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KS received research funding from PharmaEssentia Corporation, PharmaEssentia Japan KK, Chugai Pharmaceutical Co., Ltd., AbbVie GK, Kyowa Kirin Co., Ltd., Daiichi Sankyo Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Eisai Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., and\u00a0Taisho Pharmaceutical Co., Ltd; funding for medical writing and article processing charges from PharmaEssentia Japan KK; and\u00a0honoraria from Novartis Pharma KK and\u00a0Takeda Pharmaceutical Co., Ltd. AQ is the chief medical officer of PharmaEssentia. NK is\u00a0a board member of and received funding for medical writing and article processing charges from PharmaEssentia Japan KK; research funding from PharmaEssentia Corporation, Takeda Pharmaceutical Co., Ltd., and\u00a0Meiji Seika Pharma Co., Ltd.; grants from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Pharma Co., Ltd., PharmaEssentia Japan KK, Chugai Pharmaceutical Co., Ltd.,\u00a0and Perseus Proteomics Inc.; consulting fees from Japan Tobacco Inc., Torii Pharmaceutical Co., Ltd., and\u00a0PharmaEssentia Japan KK; and\u00a0honoraria from Novartis Pharma KK and\u00a0Takeda Pharmaceutical Co., Ltd. KK received research funding from PharmaEssentia Corporation; funding for medical writing and article processing charges from PharmaEssentia Japan KK; and\u00a0honoraria from Novartis Pharma KK, Takeda Pharmaceutical Co., Ltd., PharmaEssentia Japan KK, Sanofi KK, and\u00a0AbbVie GK.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}